Krystal Biotech, Inc.

Contributing Author

Recent Articles by Krystal Biotech, Inc.

Sep-03	Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference KRYS GlobeNewswire
Aug-03	Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results KRYS -8.37% GlobeNewswire
Jul-23	Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026 KRYS GlobeNewswire
May-18	Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa KRYS GlobeNewswire
May-07	Krystal Biotech to Present at BofA Securities 2026 Health Care Conference KRYS GlobeNewswire
May-04	Krystal Biotech Announces First Quarter 2026 Financial and Operating Results KRYS +7.86% GlobeNewswire
Apr-30	Krystal Biotech to Present at Upcoming Scientific Conferences KRYS GlobeNewswire
Apr-21	Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026 KRYS GlobeNewswire
Feb-24	Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference KRYS GlobeNewswire
Feb-17	Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results KRYS GlobeNewswire
Feb-10	Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 KRYS GlobeNewswire
Feb-09	Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer KRYS GlobeNewswire
Jan-11	Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference KRYS GlobeNewswire
Jan-08	Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis KRYS KRYS +5.02% GlobeNewswire
Jan-07	Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis KRYS GlobeNewswire
Jan-05	Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference KRYS GlobeNewswire
Nov-26	Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference KRYS GlobeNewswire
Nov-03	Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results KRYS GlobeNewswire
Oct-21	Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025 KRYS GlobeNewswire
Oct-14	Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis KRYS GlobeNewswire
Sep-15	Krystal Biotech Announces FDA Approval of Updated VYJUVEK Label KRYS +8.37% GlobeNewswire
Sep-02	Krystal Biotech to Present at Cantor Global Healthcare Conference 2025 KRYS GlobeNewswire
Aug-21	Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer KRYS GlobeNewswire
Aug-04	Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results KRYS -14.04% GlobeNewswire
Jul-29	Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025 KRYS GlobeNewswire
Jul-25	Krystal Biotech Announces Approval of VYJUVEK by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa KRYS GlobeNewswire
Jul-24	Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Decollete KRYS GlobeNewswire
Jul-09	Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis KRYS GlobeNewswire
Jun-24	Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa KRYS GlobeNewswire
Jun-03	Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference KRYS GlobeNewswire
May-07	Krystal Biotech to Present at BofA Securities 2025 Health Care Conference KRYS GlobeNewswire
May-06	Krystal Biotech Announces First Quarter 2025 Financial and Operating Results KRYS -14.06% GlobeNewswire

Krystal Biotech, Inc.

Recent Articles by Krystal Biotech, Inc.

Upgrade your Finviz experience